<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article173</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/TRISS" style="display:block; margin-bottom:10px;">TRISS Original</a></li>
<h2><strong>TRISS</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>
<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does a lower hemoglobin threshold for red cell transfusion in patients with septic shock affect 90-day mortality compared to a higher hemoglobin threshold?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In patients with septic shock, using a lower hemoglobin threshold (≤7 g per deciliter) for red cell transfusion compared with a higher threshold (≤9 g per deciliter) resulted in fewer transfusions without a significant difference in 90-day mortality, ischemic events, use of life support, or days alive out of the hospital.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
The current guidelines for transfusion in septic shock patients recommend maintaining a hemoglobin concentration above 7 g/dL unless the patient exhibits symptoms such as myocardial ischemia, severe hypoxemia, or ongoing hemorrhage.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
Multicenter, stratified, parallel-group, randomized, partially blinded clinical trial<br/>
N=998 adult patients with septic shock<br/>
<h2><strong>Interventions:</strong></h2><br/>
- Lower-threshold group (≤7 g per deciliter) for transfusion (n=502)<br/>
- Higher-threshold group (≤9 g per deciliter) for transfusion (n=496)<br/>
Primary outcome: Death at 90 days post-randomization<br/>
Secondary outcomes: Ischemic events, life support use, adverse reactions to transfusion, percentage of days alive without life support, and days alive out of the hospital within 90 days<br/>
Enrollment: December 2011 to December 2013<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Inclusion Criteria:<br/>
- Adult patients (≥18 years) in the ICU<br/>
- Septic shock diagnosis according to criteria<br/>
- Hemoglobin concentration ≤9 g/dL<br/>
Exclusion Criteria:<br/>
- Significant bleeding<br/>
- Requirement for ECMO<br/>
- Not specified acute myocardial infarction<br/>
Baseline Characteristics:<br/>
- Similar between both groups<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Red cell transfusions at hemoglobin ≤7 g/dL for the lower-threshold group<br/>
- Transfusions at hemoglobin ≤9 g/dL for the higher-threshold group<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcomes:<br/>
- At 90 days, mortality was 43.0% in the lower-threshold group versus 45.0% in the higher-threshold group (relative risk, 0.94; P=0.44)<br/>
Secondary Outcomes:<br/>
- Similar use of life support at days 5, 14, and 28<br/>
- Comparable numbers of ischemic events and severe adverse reactions<br/>
- No significant difference in the percentages of days alive without life support or out of the hospital<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- Lack of blinding for investigators, clinicians, and patients regarding transfusion thresholds could introduce bias.<br/>
- Limited power to detect significant differences in secondary outcomes and certain subgroup analyses.<br/>
- The choice to use leukoreduced blood, potentially limiting the applicability concerning nonleukoreduced blood.<br/>
- Trial did not specify surveillance for myocardial ischemia, possibly missing some events and resulting in detection bias.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Supported by the Danish Strategic Research Council, Copenhagen University Hospital, Rigshospitalet, the Scandinavian Society of Anaesthesiology and Intensive Care Medicine, ACTA Foundation, and others.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/><p></p>
</div>
</div>
</div>
</div>
</body>
</html>
